Phase II study to evaluate the efficacy and safety of therapy with PS 341 [bortezomib; VELCADE(RM)] in patients with advanced stage non small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Bortezomib (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 10 Dec 2007 Status changed from recruiting to discontinued.
- 25 Dec 2005 New trial record.